Western patients
AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients
AstraZeneca; AZD0120; GC012F; dual-targeting CAR-T; BCMAxCD19; multiple myeloma; DURGA-1; China; Western patients; response rate; clinical trial; CAR-T